The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 4, 2016, Pages 757-765

  Chen, Ya Tian ^a   Zhu, Feng ^a   Lin, Wei Ren ^b   Ying, Rong Biao ^b   Yang, You Ping ^b   Zeng, Ling Hui ^a  

^a ZHEJIANG UNIVERSITY CITY COLLEGE   (China)

^b Taizhou Cancer Hospital   (China)

Author keywords

Angiogenesis; EZH2; GSK126; Migration; VEGF A

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; GSK 126; METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; EZH2 PROTEIN, HUMAN; GSK126; INDOLE DERIVATIVE; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONE DERIVATIVE;

A549 CELL LINE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CELL JUNCTION; CELL MIGRATION; CHICK EMBRYO CHORIOALLANTOIC MEMBRANE ASSAY; CHORIOALLANTOIC MEMBRANE ASSAY; CONTROLLED STUDY; DOWN REGULATION; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS TUBE FORMATION ASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSWELL ASSAY; UPREGULATION; WESTERN BLOTTING; WOUND HEALING ASSAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL MOTION; CHICK EMBRYO; DRUG EFFECTS; MALE; NEOPLASM METASTASIS; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CHICK EMBRYO; HUMANS; INDOLES; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84959090816     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-2990-1     Document Type: Article

References (32)

1. Wang RF, Zhang LH, Shan LH, Sun WG, Chai CC, Wu HM, Ibla JC, Wang LF, Liu JR (2013) Effects of the fibroblast activation protein on the invasion and migration of gastric cancer. Exp Mol Pathol. doi: 10.1016/j.yexmp.2013.10.008
2. Gadducci A, Lanfredini N, Sergiampietri C (2015) Antiangiogenic agents in gynecological cancer: state of art and perspectives of clinical research. Crit Rev Oncol Hematol. doi: 10.1016/j.critrevonc.2015.05.009
3. Shen L, Cui J, Liang S, Pang Y, Liu P (2013) Update of research on the role of EZH2 in cancer progression. OncoTargets Ther 6:321-324. doi: 10.2147/OTT.S42453
4. Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE (2014) EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin 35(2):161-174. doi: 10.1038/aps.2013.161
5. Lu H, Sun J, Wang F, Feng L, Ma Y, Shen Q, Jiang Z, Sun X, Wang X, Jin H (2013) Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4. Cell Death Dis 4:e776. doi: 10.1038/cddis.2013.293
6. Takeshima H, Wakabayashi M, Hattori N, Yamashita S, Ushijima T (2015) Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis 36(2):192-201. doi: 10.1093/carcin/bgu238
7. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427):108-112. doi: 10.1038/nature11606
8. Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, Yamanaka R, Tanaka Y, Nukiwa T, Marquez VE, Ishikawa Y, Ichinose M, Aburatani H (2013) PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep 3:1911. doi: 10.1038/srep01911
9. Brooks PC, Montgomery AM, Cheresh DA (1999) Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol 129:257-269. doi: 10.1385/1-59259-249-x:257
10. Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, Voorhoeve PM, Yu Q, Tan PH, Bay BH, Itahana K, Tan P (2012) TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res Off J Am Assoc Cancer Res 18(15):4201-4212. doi: 10.1158/1078-0432.CCR-12-0036
11. Chen L, Zhu H, Pan Y, Tang C, Watanabe M, Ruan H, Wang Y, Wang J, Yao HY, Iguchi T, Wu X (2012) Ascorbic acid uptaken by sodium-dependent vitamin C transporter 2 induces betahCG expression through Sp1 and TFAP2A transcription factors in human choriocarcinoma cells. J Clin Endocrinol Metab 97(9):E1667-E1676. doi: 10.1210/jc.2012-1753
12. Gong Y, Xu CY, Wang JR, Hu XH, Hong D, Ji X, Shi W, Chen HX, Wang HB, Wu XM (2014) Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling. Cell Death Dis 5:e1544. doi: 10.1038/cddis.2014.510
13. Rojas JJ, Thorne SH (2012) Theranostic potential of oncolytic vaccinia virus. Theranostics 2(4):363-373. doi: 10.7150/thno.3724
14. Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H (2010) Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 116(12):3015-3024. doi: 10.1002/cncr.25128
15. Choi JH, Song YS, Yoon JS, Song KW, Lee YY (2010) Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS Acta Pathol Microbiol et Immunol Scand 118(3):196-202. doi: 10.1111/j.1600-0463.2009.02579.x
16. He LJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu DZ, Luo GY, Zhu SL, Xie D (2012) Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev APJCP 13(7):3173-3178
17. Huqun Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, Hagiwara K, Koyama N (2012) Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 118(6):1599-1606. doi: 10.1002/cncr.26441
18. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V (2004) Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23(34):5759-5769. doi: 10.1038/sj.onc.1207706
19. Chen X, Song N, Matsumoto K, Nanashima A, Nagayasu T, Hayashi T, Ying M, Endo D, Wu Z, Koji T (2013) High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer. Int J Oncol 43(5):1467-1480. doi: 10.3892/ijo.2013.2062
20. Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L (2015) Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget 6(5):3136-3146
21. Adhikary G, Grun D, Balasubramanian S, Kerr C, Huang JM, Eckert RL (2015) Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. Carcinogenesis 36(7):800-810. doi: 10.1093/carcin/bgv064
22. Maryan N, Statkiewicz M, Mikula M, Goryca K, Paziewska A, Strzalkowska A, Dabrowska M, Bujko M, Ostrowski J (2015) Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer. Mol Med Rep 12(1):728-736. doi: 10.3892/mmr.2015.3378
23. Bai J, Chen J, Ma M, Cai M, Xu F, Wang G, Tao K, Shuai X (2014) Inhibiting enhancer of zeste homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by activation of p21 and p16. DNA Cell Biol 33(6):337-344. doi: 10.1089/dna.2014.2340
24. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22(20):5323-5335. doi: 10.1093/emboj/cdg542
25. Tonini T, D'Andrilli G, Fucito A, Gaspa L, Bagella L (2008) Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 214(2):295-300. doi: 10.1002/jcp.21241
26. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, Zhang Y, Hong M, Shang Y (2007) Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 27(14):5105-5119. doi: 10.1128/mcb.00162-07
27. Geng J, Li X, Zhou Z, Wu CL, Dai M, Bai X (2015) EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. Cancer Lett 359(2):275-287. doi: 10.1016/j.canlet.2015.01.031
28. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G, Tarakhovsky A, Fuchs E (2009) Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136(6):1122-1135. doi: 10.1016/j.cell.2008.12.043
29. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A (2004) Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 23(28):4930-4937. doi: 10.1038/sj.onc.1207608
30. Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, Lin JT (2004) Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 11(4):517-527. doi: 10.1159/000077902
31. Ferrara N (2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29(6):789-791. doi: 10.1161/atvbaha.108.179663
32. Eswarappa SM, Fox PL (2015) Antiangiogenic VEGF-Ax: a new participant in tumor angiogenesis. Cancer Res 75(14):2765-2769. doi: 10.1158/0008-5472.can-14-3805